european patent, page-16

Hi Jarrody,

There will always remain both the for and against arguments in relation to OBJ's confidentiality agreements, however one must also accept the "against" argument will only continue to have strong support up until an announcement carrying material value to the sp is presented to the market.

Why?

Simple - because those among us who are currently opposed to the limited information for which OBJ is willing to disclose, will one day imo, become grateful for a ROI that will ultimately, on value, be attributed to these very same provisions.

I'm not having a dig at all - we all like to see some assurance that our hard earned has not been placed with too much risk and I'll be the first to agree, there are many lemmings out there.

However, I often wonder what the sp would be sitting at today if the market was privy to all information protected by these confidentially agreements? I'm not sure how many have yet to consider this but I think it's very fair to suggest many of us wouldn't be holding anywhere near the amount of shares we've accumulated up until today?

What seperates OBJ from most all other biotechnology companies listed on the ASX is that they are a technology company providing partnering services for the creation of next generation products to some of the largest multi-national companies in the world. As such their services incorporate working with some multi-billion dollar blockbuster drugs and therefor we must also accept they have been granted, under strict confidentiality provisions, access to such trade secrets belonging to some of the big boys.

These confidentially agreements are for the protection of our investment. I wouldn't want it any other way

"Trust is the universal prerequisite for a sound partnership. Before parties enter into a relationship, they must have a certain level of trust in each other. Trust can create further opportunities for partnership and collaboration. Trustworthiness, as an intangible asset, is invaluable.

During collaborations, and in some types of licensing agreements, materials and confidential information are often passed from one party to another. Confidentiality agreements are contracts that govern the disclosure of confidential information by one party to another party. The disclosure may be unilateral, bilateral, or multilateral. A confidentiality agreement is an agreement to keep confidential information secret. Confidential information is information that is valuable because it is not known to business competitors or to the public. - PIPRA - IP Handbook

Confidentiality
"OBJ believes that collaborations must be based on mutual confidentiality. OBJ will at all times respect data provided to it by its Collaborators and expects Collaborators to respect the confidentiality of OBJ's technologies and knowhow, especially in new and evolving opportunities, perhaps beyond the scope of initial discussions. OBJ will not use Collaborators data for any IP purpose without permission and requires the same level of commitment from its Collaborators.
_____

You know I can't let this one slip through maka ;)

"The reality is it will take years to get to any meaningful position with pain control patches if developing on your own. Just to give you an idea, that other competitor is about to go into Phase II/III trials for Oxy patch has been working on it for over 2 years now and expects upon successful completion of trials to have patch commercially available and FDA approved sometime in 2013. That's at least 4 years from first embarking on the project to delivery."

This recent annoucnement in respect to pain patches and going it alone was a little disconcerting for me. It did smell a little bit of frustration to me.
___

OBJ's new pain patch program is based on OBJ's decision to develop value-added and market ready products for distribution either directly or through channel partners. - To my understanding this option will always be open to them.

A consumer concept and market research program has already been completed. They have been working on this since 2010, as they have already advised. It's also to my understanding that they already have a number of formulations which they may choose from that will be optimized during this development program.

I also very much doubt OBJ s/holders will be funding this program.
___

With regards to your other mention, I think you might find poh announced the results of its Oxycodone Phase 1 clinical trial back in 2007 - 4 years ago!

Nice try tiger ;)